Navigation Links
InfoLogix Announces Second Quarter Financial Results

HATBORO, Pa., Aug. 13 /PRNewswire-FirstCall/ -- InfoLogix, Inc. (Nasdaq: IFLG), a leading technology provider of enterprise mobility solutions for the healthcare and commercial industries, today announced financial results for the quarter ended June 30, 2009.

(Logo: )

Second Quarter 2009 Financial Results

David T. Gulian, president and chief executive officer of InfoLogix, said: "We remain committed to our vision of becoming the leading provider of enterprise mobility solutions for the healthcare and commercial markets, by providing enhanced implementation and integration services, software systems and mobile managed services. Although some customers have postponed IT projects to conserve capital resources in the current economic environment, which resulted in lower revenue for us in the second quarter of 2009 compared to the same period in 2008, our net revenues for the second quarter of 2009 were up by almost 30% from last quarter."

Net revenues for the quarter ended June 30, 2009 were $24.4 million, down 7.2% from $26.3 million in last year's second quarter. The revenue decrease was a result of the overall macroeconomic environment's effect on our customers, which has led to the continued deferral of several significant projects to later in the third and fourth quarters of 2009.

Gross profit for the quarter ended June 30, 2009 was $4.6 million, or 18.8% of net revenues, compared to $7.3 million or 27.7% of net revenues in the second quarter of 2008. Lower gross margins in the comparable periods were the result of project delays in our consulting and professional services resulting in such higher margin services comprising less of the overall revenue mix, and an increase in large infrastructure projects that had lower gross margins.

Selling, general and administrative expenses were $7.7 million for the three months ended June 30, 2009, compared with $7.6 million for the three months ended June 30, 2008, an increase of $136 thousand, or 1.8%. The small increase in selling, general and administrative expenses was primarily attributable to higher salary expense as a result of more sales and pre-sales representatives, as well as higher administrative salaries and related employment benefits from the acquisitions made in the second quarter of 2008, each partially offset by continued cost reduction actions taken since the fourth quarter of 2008. Selling expenses were $2.9 million for the three months ended June 30, 2009, compared with $2.9 million for the three months ended June 30, 2008, which was an increase of $86 thousand, or 3.0%. General and administrative expenses were $4.8 million for the second quarter 2009, compared with $4.8 million for the second quarter of 2008, which was an increase of $51 thousand, or 1.1%.

Interest expense was $1.2 million for the three months ended June 30, 2009, compared to approximately $0.6 million for the three months ended June 30, 2008, an increase of approximately $0.6 million or 91.8%. The increase in interest expense is a result of significantly higher base and default rates charged on our revolving credit and term loan facilities and higher amounts outstanding under these facilities in the second quarter of 2009.

InfoLogix reported a net loss of $4.8 million, or $0.19 per basic and diluted share, for the quarter ended June 30, 2009, compared with a net loss of approximately $0.5 million, or $0.02 per basic and diluted share for the same period of 2008.

Liquidity and Capital Resources

At June 30, 2009 InfoLogix had cash of $3.5 million and total debt, including current and long term, of $25.2 million, as well as an accumulated stockholders' deficit of $1.0 million. David Gulian said: "In an effort to meet the challenges of the current economic environment, we continue to align our cost structure with our adjusted business model, and expect to realize the benefits of these changes in the coming quarters of 2009. We are in default of our credit agreement with our senior lender, but have recently entered into a forbearance agreement (a description of which is included in our Form 8-K filed with the Securities and Exchange Commission on August 5, 2009). If we fail to refinance our debt obligations, secure additional capital and improve our liquidity in the near term, our senior lender may choose to accelerate our debt obligations. As we do not have sufficient liquidity to meet those obligations, if the debt is accelerated, we may not be able to continue as a going concern. We are seeking to improve our liquidity and capital resources in the near term, which would allow us to focus even more on growing our core business. We are engaged in ongoing discussions with numerous parties regarding securing additional funding and refinancing our debt obligations, have received several indications of interest from equity investors, asset-based and other lenders, and strategic investors, and are making progress with several parties in discussing the details and establishing the terms of these proposed capital arrangements."

About InfoLogix, Inc.

InfoLogix is a leading provider of enterprise mobility solutions for the healthcare and commercial industries. InfoLogix uses the industry's most advanced technologies to increase the efficiency, accuracy, and transparency of complex business and clinical processes. With 19 issued patents, InfoLogix provides mobile managed solutions, on-demand software applications, mobile infrastructure products, and strategic consulting services to over 2,000 clients in North America including Kraft Foods, Merck and Company, General Electric, Kaiser Permanente, MultiCare Health System and Stanford School of Medicine. InfoLogix is a publicly-traded company (Nasdaq: IFLG).

Safe Harbor

InfoLogix makes forward-looking statements in this press release which represent our expectations or beliefs about future events and financial performance. Forward-looking statements are identifiable by words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Forward-looking statements are subject to known and unknown risks and uncertainties, including the risks described in our Annual Report on Form 10-K for the period ended December 31, 2008 and other filings we make with the Securities and Exchange Commission. In addition, actual results could differ materially from those suggested by the forward-looking statements, and therefore you should not place undue reliance on the forward-looking statements. We do not make any commitment to revise or update any forward-looking statements to reflect events or circumstances occurring or existing after the date of any forward-looking statement is made.

                                      INFOLOGIX, INC.
                    (in thousands, except share and per share amounts)

                                  Three Months Ended        Six Months Ended
                                       June 30,                 June 30,
                                    2009        2008        2009        2008

    Net revenues                 $24,411     $26,347     $43,223     $50,134
    Cost of revenues              19,833      19,059      34,510      36,641

       Gross profit                4,578       7,288       8,713      13,493
    Selling, general and
     administrative expenses       7,748       7,612      15,411      15,128

       Operating loss             (3,170)       (324)     (6,698)     (1,635)
    Interest expense              (1,189)       (619)     (2,334)       (907)
    Interest income                    5          32          15          79
    Loss on extinguishment of
     debt                           (420)          -        (420)          -

       Loss before income tax
        benefit (provision)       (4,774)       (911)     (9,437)     (2,463)
    Income tax benefit
     (provision)                      (7)        371         (14)        930

       Net loss                  $(4,781)      $(540)    $(9,451)    $(1,533)

    Loss per share - basic
     and diluted                  $(0.19)     $(0.02)     $(0.37)     $(0.06)

    Weighted average shares
     outstanding - basic and
     diluted                  25,685,196  25,193,700  25,644,173  25,056,071

                              INFOLOGIX, INC.
                 Condensed Consolidated Balance Sheets
                  (in thousands, except share amounts)

                                                       June 30,  December 31,
                                                          2009          2008
    Currents assets:
      Cash and cash equivalents                       $3,518        $3,037
      Accounts and other receivables (net of allowance
       for doubtful accounts in the amount of $572 and
       $352 as of June 30, 2009 and December 31, 2008,
       respectively)                                  17,123        22,610
      Unbilled revenue                                   261         1,498
      Inventory, net                                   2,272         1,775
      Prepaid expenses and other current assets        1,651         1,228

         Total current assets                         24,825        30,148
    Property and equipment, net                          781           944
    Intangible assets, net                             8,215         8,709
    Goodwill                                          10,971        10,540
    Deferred financing costs                             264           501

         Total assets                                $45,056       $50,842

    Current liabilities:
      Accounts payable                               $11,584       $11,389
      Line of credit                                   9,012         9,000
      Current portion of notes payable                11,552        12,077
      Current portion of capital lease obligations        81            86
      Sales tax payable                                  102           477
      Accrued expenses                                 3,889         2,800
      Accrued earn out payable                         2,388         1,958
      Other current liabilities                        1,360           900
      Deferred revenue                                 1,887           276

         Total current liabilities                    41,855        38,963
    Notes payable, net of current maturities           4,346         4,215
    Capital lease obligations, net of current
     maturities                                          155           186

         Total liabilities                            46,356        43,364

    Commitments and Contingencies

    Stockholders' (deficiency) equity:
      Preferred stock, par value $.00001; authorized
       10,000,000 shares; none issued or outstanding       -             -
      Common stock, par value $.00001; authorized
       100,000,000 shares; issued and outstanding
       25,759,135 shares and 25,602,267 shares at
       June 30, 2009 and December 31, 2008,
       respectively                                        -             -
      Additional paid in capital                      26,439        25,766
      Accumulated deficit                            (27,739)      (18,288)

         Total stockholders' (deficiency) equity      (1,300)        7,478

         Total liabilities and stockholders'
          (deficiency) equity                        $45,056       $50,842

                         INFOLOGIX, INC.
      Condensed Consolidated Statements of Cash Flows (Unaudited)
                          (in thousands)

                                                    Six Months Ended June 30,
                                                            2009    2008

    Operating activities:
    Net cash provided by (used in) operating activities   $1,259   $(774)

    Investing activities:
      Acquisition of property, software and equipment       (413) (1,339)
      Acquisitions, net of cash acquired                       -  (2,975)
      Disposal of property and equipment                       -      27
      Promissory notes issued                                  -    (200)
    Net cash used in investing activities                   (413) (4,487)

    Financing activities:
      Payments received from employee stock purchase plan     65      31
      Proceeds from issuance of warrants                      78       -
      Payment of deferred financing costs                    (90) (1,348)
      Issuance of Hercules note payable                        -   9,000
      Issuance of Hercules line of credit                      -   7,500
      Final repayment of Sovereign notes payable               -  (3,292)
      Final repayment of Sovereign line of credit              -  (9,334)
      Repayment of long-term debt and capital leases        (430)   (214)
      Net borrowings on line of credit                        12   1,856
    Net cash (used in) provided by financing activities     (365)  4,199

    Net change in cash and cash equivalents                  481  (1,062)

    Cash and cash equivalents at beginning of period       3,037   6,101

    Cash and cash equivalents at end of period            $3,518  $5,039

    John A. Roberts
    Chief Financial Officer
    215-604-0691, x1102

SOURCE InfoLogix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. InfoLogix Announces Approval for NASDAQ Listing
2. InfoLogix Acquires Healthcare Informatics Associates Inc. (HIA); Adds Premier Healthcare Consulting Firm and Systems Integrator
3. InfoLogix Signs Largest International Deal to Date with Healthcare Solutions Agreement in United Arab Emirates
4. InfoLogix to Report Third Quarter and Nine Month Financial Results on November 8, 2007
5. InfoLogix Featured in FOX Business News Interview on Reducing Healthcare Medication Errors - Video Available Online
6. InfoLogix, Inc. to Present at the Growth & Investor Conference in Fort Lauderdale, FL
7. Dollar Thrifty Automotive Group Expands Mobile Managed Services Contract with InfoLogix
8. InfoLogix to Report First Quarter Results on April 30, 2008
9. InfoLogix Announces First Quarter 2008 Financial Results
10. InfoLogix to Report First Quarter Results on April 30, 2008 - Conference Call Information
11. InfoLogix Completes $25 Million Senior Debt Financing
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... The holiday ... dish and pleasing the palates of attendees is of the utmost importance. Whether ... a seasonal get-together, give these recipes a try this holiday season. , Turkey ...
(Date:11/25/2015)... Nairobi (PRWEB) , ... November 26, 2015 , ... ... African Union Commission (AUC), European Union (EU), ANDI Pan African Centres of Excellence, ... Nations Office in Nairobi (UNON) for the opening of the 5th African Network ...
(Date:11/25/2015)... ... 25, 2015 , ... Dental professionals who would like to become more proficient ... attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will be held ... the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud ...
(Date:11/25/2015)... ... 2015 , ... Smiles by Stevens is pleased to announce the ... While many patients are aware of the benefits of Botox® in the treatment of ... suffering with discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular ...
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I saw a ... “I thought there had to be a convenient and comfortable way to protect them ... enables disabled individuals to safely travel during cold or inclement weather. In doing so, ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... -- ) has announced the ... Viscosity Drugs" report to their offering. ... of the "Self Administration of High Viscosity ... Research and Markets ( ) has ... of High Viscosity Drugs" report to their ...
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Marker Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
Breaking Medicine Technology: